Using Cytochalasins to Improve Current Chemotherapeutic Approaches

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)

Volume 17, 14 Issues, 2017

Download PDF Flyer

Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Michelle Prudhomme
Institut de Chimie de Clermont-Ferrand
Université Clermont Auvergne

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Using Cytochalasins to Improve Current Chemotherapeutic Approaches

Anti-Cancer Agents in Medicinal Chemistry, 15(3): 327-335.

Author(s): Matthew Trendowski.

Affiliation: Department of Biology, Syracuse University, 107 College Place, Syracuse, NY 13244, USA.


Although the amount of progress cancer therapy has made in recent years is commendable, considerable limitations still remain. Most agents preferentially target rapidly proliferating cells, thereby destroying tumorigenic growths. Unfortunately, there are many labile cells in the patient that are also rapidly dividing, ultimately perpetuating significant side effects, including immunosuppression. Cytochalasins are microfilament-directed agents most commonly known for their use in basic research to understand cytoskeletal mechanisms. However, such agents also exhibit profound anticancer activity, as indicated by numerous in vitro and in vivo studies. Cytochalasins appear to preferentially damage malignant cells, as shown by their minimal effects on normal epithelial and immune cells. Further, cytochalasins influence the end stages of mitosis, suggesting that such agents could be combined with microtubule-directed agents to elicit a profound synergistic effect on malignant cells. Therefore, it is likely that cytochalasins could be used to supplement current chemotherapeutic measures to improve efficacy rates, as well as decrease the prevalence of drug resistance in the clinical setting.


Actin, apoptosis, chemotherapy, cytochalasins, drug resistance, immunosuppression, microfilaments, preferential damage.

Download Free Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 15
Issue Number: 3
First Page: 327
Last Page: 335
Page Count: 9
DOI: 10.2174/1871520614666141016164335

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science